Ronald A. Salerno

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

Lawrence J. Lesko, Ronald A. Salerno, Brian B. Spear et al. · The Journal of Clinical Pharmacology · 2003 · 123 citations

Safe Harbor, Genetics, Dna Sequences +19

Relationships Between Aryl Hydrocarbon Hydroxylase Inducibility and Sensitivity to Chemically Induced Subcutaneous Sarcomas in Various Strains of Mice23

Richard E. Kouri, Ronald A. Salerno, Carrie E. Whitmire · JNCI Journal of the National Cancer Institute · 1973 · 98 citations

Tumor Biology, Malignant Disease, Oncogenic Agent +15

Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal

Ronald A. Salerno, Lawrence J. Lesko · Pharmacogenomics · 2004 · 49 citations

Regulatory Decision-making, Genomic Data Submission, Medicine +10

Pharmacogenomic Data: FDA Voluntary and Required Submission Guidance

Ronald A. Salerno, Lawrence J. Lesko · Pharmacogenomics · 2004 · 46 citations

Fda Voluntary, Medicine, Pharmacogenomics +3

RNA Tumor-Virus Antigen Expression in Chemically Induced Tumors. Virus-Genome-Specified Common Antigens Detected by Complement Fixation in Mouse Tumors Induced by 3-Methylcholanthrene<xref ref-type="fn" rid="FN1">2</xref>

Carrie E. Whitmire, Ronald A. Salerno, Louise S. Rabstein et al. · JNCI Journal of the National Cancer Institute · 1971 · 41 citations

Complement Fixation, Natural Gene Inheritance, Immunology +17